GentleCare -Brand name

Diabetic ulcer is a complication of diabetes. Currently, there are more than 30 million people suffer with diabetes and 25% of those patients will develop diabetic ulcer. Diabetic ulcer treatments are very expensive and not highly effective, which leads to foot amputation which costs patients even more than one time treatment.

Early Stage:

Patent Analysis - Completed (Freedom to operate)
US-based Market analysis completed
Need funding for Proof of concept testing
Need $150.000 - for pre-clinical trials
$250.000 -for Clinical Trial.
In vitro and vivo studies completed.

Problem
Review related to the costs of lower limb amputations, the range lies between US$16,488 and US$66,215 (1998 currency).The cost was found higher in the amputation procedure and its associated nursing and institutional care compared with costs included in the surgical procedure. It showed that for minor lower limb amputation (only at foot level), the cost was US$43,800, while the major lower limb amputations (above ankle) was US$66,215 . In these studies it was observed that a substantial part of the expenditure was not incurred in the surgeries, but included rehabilitation medicine, nursing homes and internal medicine. The conclusions derived from these studies clearly state that prevention of DFUs and lower limb amputations may be the most effective way to reduce the high cost.
Cost of single treatment of diabetic ulcer in a hospital - $3000

GentleCare is designed two solve two problems - To provide more effective treatment at affordable cost which apparently will prevent foot amputation.

Direct competitor: ConvaTec Inc.,

Indirect: 3M Healthcare Ltd., Coloplast A/S, B.Braun, Smith & Nephew, Molnlycke Health Care, BSN Medical and Acelity.

-Advanced fast healing properties
-Affordable cost
-Prevents infections

To be negotiated

To be negotiated

Lots of competitors.

GIST Business Incubation Program 2019.

A Stipend for participation in the GIST Business Incubation Program 2019.